Table 2 Comparison of clinical outcomes between the two groups
Intravenous to oral therapy group (n = 21) | Intravenous therapy group (n = 52) | p-value | |
|---|---|---|---|
Duration of linezolid treatment (days) | 12 ± 5.8 | 14 ± 5.6 | 0.22 |
Reduction in level of CRP from baseline of ≥30 % (n [%]) | 16 (76.2) | 38 (73.1) | 0.78 |
Reduction in platelet count from baseline of ≥30 % (n [%]) | 7 (33.3) | 20 (38.5) | 0.68 |
Re-administration of an anti-MRSA agent <90 days after hospital discharge (n [%]) | 2 (9.5) | 7 (13.5) | 0.64 |
Death <28 days after hospital discharge (n [%]) | 3 (14.3) | 10 (19.2) | 0.62 |
Drug costs (/day/person) | US$222 | US$305 | <0.001 |